It looked like the writing was on the wall for Alligator Biosciences after the Swedish company slashed its workforce and ended its early-stage R&D activities at the end of last year but 2025 has started well for the firm and its pancreatic cancer candidate, mitazalimab.
Cash-strapped Alligator said in December that it would “adjust the size of its organization and scope of operations” to reflect...
Welcome to Scrip
Create an account to read this article
Already a subscriber?